Company Description
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.
The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.
It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.
The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.
| Country | Germany |
| Founded | 1992 |
| IPO Date | Mar 9, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 524 |
| CEO | Arkadius Pichota M.B.A., Ph.D. |
Contact Details
Address: Semmelweisstr. 7 Planegg, 2M 82152 Germany | |
| Phone | 49 89 89927-0 |
| Website | morphosys.com |
Stock Details
| Ticker Symbol | MOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001340243 |
| CUSIP Number | 617760202 |
| ISIN Number | US6177602025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman of Management Board, MD and Chief Executive Officer |
| Dr. Lucinda Crabtree Ph.D. | Chief Financial Officer and Member of Management Board |
| Charlotte Lohmann | Chief Legal and Human Resources Officer and Member of Management Board |
| Klaus De Wall | Head of Accounting and Tax |
| Dr. Margit Urban | Head of Discovery Alliances and Technologies |
| Dr. Julia Neugebauer Ph.D. | Head of Investor Relations |
| Dr. Barbara Krebs-Pohl Ph.D. | Chief Business Officer |
| Dr. Günter Wellnhofer | Head of Technical Operations |
| Dr. Harald Watzka | Head of Alliance Management |
| Yen Ching Chua | Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2024 | SC TO-T/A | Filing |
| Jul 18, 2024 | 6-K | Report of foreign issuer |
| Jul 12, 2024 | 6-K | Report of foreign issuer |
| Jul 11, 2024 | SC TO-T/A | Filing |
| Jul 5, 2024 | SC 14D9 | Filing |
| Jul 5, 2024 | SC TO-T | Filing |
| Jul 2, 2024 | 6-K | Report of foreign issuer |
| Jun 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 21, 2024 | 6-K | Report of foreign issuer |
| Jun 20, 2024 | 6-K | Report of foreign issuer |